设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2021 年第 12 期 第 16 卷

热毒宁联合阿糖腺苷治疗传染性单核细胞增多症患儿的临床效果及对T淋巴细胞亚群和炎症因子水平的影响

Clinical effect of Reduning combined with vidarabine on infectious mononucleosis and its effect on T lymphocyte subsets and inflammatory factor levels

作者:徐晓梅1高健2陈必全1

英文作者:Xu Xiaomei1 Gao Jian2 Chen Biquan1

单位:1安徽省儿童医院感染科,合肥230001;2安徽省儿童医院风湿免疫科,合肥230001

英文单位:1Department of Infectious Disease Anhui Provincial Children′s Hospital Hefei 230001 China; 2Department of Rheumatology and Immunology Anhui Provincial Children′s Hospital Hefei 230001 China

关键词:传染性单核细胞增多症;注射用单磷酸阿糖腺苷;热毒宁注射液;应用效果

英文关键词:Infectiousmononucleosis;Vidarabinemonophosphateforinjection;Reduninginjection;Applicationeffect

  • 摘要:
  • 目的 观察热毒宁注射液联合注射用单磷酸阿糖腺苷治疗传染性单核细胞增多症患儿的临床效果及对T淋巴细胞亚群和炎症因子水平的影响。方法 选取20171月至201912月安徽省儿童医院收治的90例传染性单核细胞增多症患儿。按照随机数字表法分为观察组和对照组,各45例。对照组采用注射用单磷酸阿糖腺苷治疗,观察组采用热毒宁注射液联合注射用单磷酸阿糖腺苷治疗,2组治疗周期均为7 d。比较2组治疗效果、T淋巴细胞亚群和炎症因子水平变化以及药物不良反应发生情况。结果  观察组总有效率高于对照组,差异有统计学意义[93.3%42/45)比80.0%36/45)](P<0.05)。治疗后,2CD+4CD+4/CD+8比值及白细胞介素2IL-2)水平均高于治疗前、且观察组高于对照组,CD+8IL-10水平均低于治疗前、且观察组低于对照组,差异均有统计学意义(均P0.05)。2组药物不良反应发生率差异无统计学意义(P0.05)。结论  对传染性单核细胞增多症患儿,使用热毒宁注射液联合注射用单磷酸阿糖腺苷进行治疗,有助于提升临床治疗效果,改善患儿T淋巴细胞亚群和炎症因子平衡情况,且安全性较高。

  • Objective To observe the clinical effect of Reduning injection combined with vidarabine monophosphate for injection on infectious mononucleosis and its effect on T lymphocyte subsets and inflammatory factor levels. Methods Totally 90 children with infectious mononucleosis treated in Anhui Provincial Childrens Hospital from January 2017 to December 2019 were selected. According to the random number table method, they were divided into observation group and control group, with 45 cases in each group. The control group was treated with vidarabine monophosphate for injection, and the observation group was treated with Reduning injection combined with vidarabine monophosphate for injection. The treatment cycle of the two groups was 7 d. After stage treatment, the curative effect, changes of T lymphocyte subsets and inflammatory factor levels and the occurrence of adverse drug reactions were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group93.3%(42/45) vs 80.0%(36/45)(P<0.05). After treatment, the levels of CD+4, CD+4/CD+8 ratio and interleukin-2 (IL-2) in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group; the levels of CD+8 and IL-10 in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group(all P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05). Conclusion  Reduning injection combined with vidarabine monophosphate for injection in the treatment of chlidren with infectious mononucleosis is helpful and safe to improve the clinical effect and to improve the T lymphocyte subsets and inflammatory factor balance.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭